Physician profile
Eric Christopher Hames
NPI 1174917116
$1,381.06
in general payments reported to CMS, 2019-2025
15 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $122 · 2021: $15.44 · 2023: $33.46 · 2024: $143 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $289.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $240.39 | 2019-2023 | Breztri |
| Lilly USA, LLC | $176.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $146.56 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.26 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $97.96 | 2019-2025 | Shingrix |
| Amgen INC. | $69.95 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $54.81 | 2019 | |
| Amarin Pharma, INC. | $40.64 | 2019 | |
| Genentech USA, INC. | $40.35 | 2019 | |
| Ironshore Pharmaceuticals INC. | $30.00 | 2019 | |
| Merck Sharp & Dohme LLC | $28.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.96 | 2019-2020 | |
| Sanofi Pasteur INC. | $23.69 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $16.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.